Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Next Previous
Trial Profile

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Seclidemstat (Primary) ; Topotecan (Primary)
  • Indications Chondrosarcoma; Clear cell sarcoma; Ewing's sarcoma; Fibrous-tissue-neoplasm; Histiocytoma; Myxoid liposarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Sponsors Salarius Pharmaceuticals

Most Recent Events

  • 04 Aug 2022 According to a Salarius Pharmaceuticals media release, the company expects to report interim data updates in the second half of 2022.
  • 04 Aug 2022 According to a Salarius Pharmaceuticals media release, the company announces the addition of four prestigious institutions to this trial. The Seattle Cancer Care Alliance (SCCA) which is comprised of the Fred Hutchinson Cancer Research Center, Seattle Children's Hospital and University of Washington Medical Center as well as Oregon Health & Sciences University in Portland are now supporting trial enrollment.
  • 10 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top